Cardiff Oncology Inc (CRDF) News

Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge

Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge PR...

Form 8-K - Current report

Form S-3 - Registration statement under Securities Act of 1933

Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

- Robust initial efficacy signal with onvansertib + chemo/bev in ongoing first-line RAS-mut metastatic...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Cardiff Oncology to Present at Upcoming Investor Conferences

SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage...

Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF) (“Cardiff Oncology” or the...

Form 8-K - Current report

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

- Initial results from randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care in RAS-mut...